Pacira BioSciences, Inc. $PCRX Shares Acquired by Three Seasons Wealth LLC

Three Seasons Wealth LLC increased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 43.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,942 shares of the company’s stock after buying an additional 19,107 shares during the period. Three Seasons Wealth LLC owned about 0.16% of Pacira BioSciences worth $1,597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. raised its position in Pacira BioSciences by 5,900.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock worth $39,000 after acquiring an additional 1,475 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Pacira BioSciences in the first quarter valued at about $46,000. Kestra Advisory Services LLC acquired a new stake in shares of Pacira BioSciences in the fourth quarter valued at about $48,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Pacira BioSciences in the fourth quarter valued at about $51,000. Finally, Global Retirement Partners LLC purchased a new stake in shares of Pacira BioSciences during the second quarter worth about $51,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Stock Performance

NASDAQ:PCRX opened at $26.35 on Friday. The company has a market cap of $1.05 billion, a P/E ratio of 75.29 and a beta of 0.26. Pacira BioSciences, Inc. has a twelve month low of $18.80 and a twelve month high of $27.66. The company’s 50-day moving average price is $25.43 and its 200-day moving average price is $24.00. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The company had revenue of $192.40 million during the quarter, compared to analysts’ expectations of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. Pacira BioSciences’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.74 EPS. On average, sell-side analysts forecast that Pacira BioSciences, Inc. will post 1.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PCRX. Needham & Company LLC raised their price target on shares of Pacira BioSciences from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Truist Financial initiated coverage on Pacira BioSciences in a research note on Monday, August 17th. They set a “buy” rating and a $30.00 price objective for the company. Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 16th. Royal Bank Of Canada raised their target price on Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a research note on Wednesday, July 1st. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Pacira BioSciences has a consensus rating of “Hold” and a consensus price target of $30.20.

Insider Activity at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,040 shares of Pacira BioSciences stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the transaction, the insider owned 216,384 shares in the company, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total value of $143,702.50. Following the transaction, the senior vice president directly owned 62,284 shares in the company, valued at $1,463,674. This trade represents a 8.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.